Diabetes pill may reverse early heart damage, small study suggests
NCT ID NCT07186153
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks at whether common diabetes drugs called SGLT2 inhibitors (like empagliflozin and dapagliflozin) can improve the structure and function of the heart's left atrium in people with type 2 diabetes. Researchers will use advanced ultrasound to measure heart changes in 100 adults aged 40-75 before and after 6 months of treatment. The goal is to see if these drugs can reverse early signs of heart strain caused by diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT2 inhibitors (empagliflozin, dapagliflozin)
What this could lead to
If successful, this could show that SGLT2 drugs help reverse early heart damage in people with diabetes, potentially reducing future heart failure risk.
What could go wrong
This is a small, early-phase study with only 100 participants and no control group. Results may not apply to all diabetes patients, and the heart changes measured may not translate to fewer heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••